Patent application number | Description | Published |
20090142070 | Methods and apparatus for supporting fiber span loss and dispersion measurements in the presence and absence of dispersion compensation elements - An example embodiment of the invention includes a method and apparatus for supporting fiber span loss and dispersion measurements in the presence or absence of dispersion compensation elements (DCE). The technique may be used to configure a network link by accessing an optical signal at an ingress side of a connection point for a DCE coupling an egress side of a fiber span at the ingress side of the DCE to an optical amplifier at a connection point for an egress side of the DCE. The technique may include determining chromatic dispersion of the fiber span based on the optical signal and reporting information associated with chromatic dispersion. As a result, the technique may be used, for example, during initial system installation when user data signals and the DCE are not present as well as after the network begins carrying user traffic and after a DCE has been installed. | 06-04-2009 |
20090252497 | Method and apparatus for compensating for polarization mode dispersion (PMD) - Current optical networks are engineered to handle amplifier noise and chromatic dispersion. Polarization mode dispersion occurs in optical networks due splitting of the light energy of a pulse propagating in a fiber into two modes. Compensating for polarization mode dispersion is a difficult and expensive task and hence only few commercial systems have been deployed to deal with this issue. A polarization mode dispersion compensation module according to an example embodiment of the present invention compensates for polarization mode dispersion by determining a performance metric related to an error rate of an optical signal in at least one polarization mode in a filtered state. Based on the performance metric, a control vector is determined to control the optical signal in the at least one polarization mode in the filtered state. The control vector is then applied to a polarization effecting device to compensate for polarization mode dispersion. | 10-08-2009 |
20090285585 | Method and apparatus for polarization stabilization in optical receivers with complex modulation formats - High optical communication rates are making their way into networks initially designed for 10 Gigabits per seconds (Gbps). These higher rates of 40 Gbps and higher have shorter signaling periods and are more susceptible to differential group delay (DGD). A method and corresponding apparatus in an example embodiment of the present invention compensates for polarization state sensitivity of a receiver by determining a performance metric relating to an error rate due to transmission and reception of a modulated optical signal in a medium introducing DGD. Based on the performance metric, a control vector is determined to control a polarization state of the modulated optical signal. The control vector is applied to a polarization effecting device to compensate for the DGD and the polarization state sensitivity of the receiver. Communication rates of 40 Gbps and higher can be used in transmission mediums that introduce DGD through use of embodiments presented. | 11-19-2009 |
20100040364 | Method and apparatus for reducing cost of an optical amplification in a network - Signals propagating in wavelength division multiplexing (WDM) optical networks suffer from loss, which decreases optical signal-to-noise ratios (OSNRs) and degrades a quality of received transmissions. Present methods of boosting OSNRs involve regeneration using transponders, which scale in complexity with the number of WDM channels. Optical amplifiers may boost signal strength, but amplified spontaneous emission (ASE) noise often reduces OSNR despite increases in signal strength, although changing the amplifier operating settings may reduce emitted ASE noise power. A method or corresponding apparatus in an example embodiment of the present invention provides a planning tool for deploying optical amplifiers in an optical network in a manner that reduces the need for optical regeneration, reducing cost and complexity of the deployed network. In one embodiment, the disclosed planning tool may substitute models of high-gain amplifiers operating at low settings for models of low-gain amplifiers operating at high settings. | 02-18-2010 |
20100142956 | Method and Apparatus for Reshaping a Channel Signal - Higher rate channels (e.g., 40 Giga bits or greater) have large bandwidths and are susceptible to inter-channel crosstalk. Optical tunable filters may be used to overcome crosstalk. Tunable filters do not maintain their central wavelength over a long duration or a wide temperature range. An example embodiment of the present invention relates to shaping a channel signal within a dense wavelength division multiplexing signal and may employ a tunable filter and input and output optical power detectors to measure a modulated source channel signal at an input of the tunable filter and a filtered modulated source channel signal at an output of the tunable filter. A controller is configured to adjust a center wavelength of the tunable filter as a function of a difference between measurements of optical power by the optical power detectors. Adjusting the center wavelength shapes the channel signal and overcomes undesired effects for higher rate channels. | 06-10-2010 |
20100322621 | OSNR MODEL FOR OPTICAL ENGINEERING RULES USED IN A PLANNING TOOL - Increasing data rates in next-generation optical networks requires a change in the type of optical modulation used to encode optical signals carried by the optical networks. Different types of optical modulation incur different optical impairments, which may degrade the fidelity of the optical signals by reducing the optical signal-to-noise ratio (OSNR). A method or corresponding apparatus in an example embodiment of the present invention provides a planning tool for deploying an optical network in a manner based on the optical modulation that reduces the cost and complexity of the deployed network. In one embodiment, the disclosed planning tool may adjust a model of the optical network to be deployed by changing the topology and/or the number and/or type of optical network elements in response to optical impairments for a given optical modulation. | 12-23-2010 |
20120154904 | METHOD AND APPARATUS FOR GAIN TILT COMPENSATION OVER FIBER OPTIC CABLE - An embodiment of the invention comprises determining a gain tilt based on power measurements from a power measurement block, determining a noise figure penalty based on the gain tilt, determining a gain tilt compensation to compensate for the gain tilt taking into account the noise figure penalty, and communicating the gain tilt compensation to an amplifier block to apply the gain tilt compensation to subsequently received wavelengths. | 06-21-2012 |
20130272697 | OSNR Model For Optical Engineering Rules Used In A Planning Tool - Increasing data rates in next-generation optical networks requires a change in the type of optical modulation used to encode optical signals carried by the optical networks. Different types of optical modulation incur different optical impairments, which may degrade the fidelity of the optical signals by reducing the optical signal-to-noise ratio (OSNR). A method or corresponding apparatus in an example embodiment of the present invention provides a planning tool for deploying an optical network in a manner based on the optical modulation that reduces the cost and complexity of the deployed network. In one embodiment, the disclosed planning tool may adjust a model of the optical network to be deployed by changing the topology and/or the number and/or type of optical network elements in response to optical impairments for a given optical modulation. | 10-17-2013 |
20130279908 | RECONFIGURABLE OPTICAL ADD/DROP MULTIPLEXER NETWORK ELEMENT FOR C-BAND AND L-BAND OPTICAL SIGNALS - A method for routing C-band and L-band optical signals, and a system, apparatus, and computer program that operate in accordance with the method. The method comprises selecting one or more C-band optical signals using one or more C-band components, resulting in one or more selected C-band optical signals. One or more L-band optical signals are selected using one or more L-band components, resulting in one or more selected L-band optical signals. The selected C-band and L-band optical signals are combined. | 10-24-2013 |
20150055952 | INTRANODAL ROADM FIBER MANAGEMENT APPARATUSES, SYSTEMS, AND METHODS - An intranodal reconfigurable optical add/drop multiplexer (ROADM) fiber management apparatus, and a system employing the apparatus. The apparatus comprises a plurality of ingress optical ports, a plurality of egress optical ports, and a plurality of optical interconnections interposed between ones of the plurality of ingress optical ports and ones of the plurality of egress optical ports. Each of the plurality of ingress optical ports corresponds to one of the plurality of egress optical ports. Each one of the plurality of ingress optical ports is optically coupled by way of the optical interconnections to at least one of the plurality of egress optical ports. Each one of the plurality of egress optical ports is optically coupled by way of the optical interconnections to at least one of the plurality of ingress optical ports. | 02-26-2015 |
Patent application number | Description | Published |
20090263379 | MONOCLONAL ANTIBODIES FOR INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS - Using gene array technology, we observed that an increase of the alpha-4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we confirmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both alpha-4 and β1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells. | 10-22-2009 |
20110020371 | POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer. | 01-27-2011 |
20110212048 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM - A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms. | 09-01-2011 |
20120328555 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER - The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. | 12-27-2012 |
20130084261 | POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY - The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer. | 04-04-2013 |
20140039125 | POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM - A drug delivery system for delivering a drug payload to a specific tissue or cell type is disclosed. The system includes a polymalic acid molecular scaffold which can be used for attaching a plurality of molecular modules. Molecular modules include targeting antibodies for promoting cellular uptake by a target cell, and pro-drugs for altering cellular metabolism, for example, a pro-drug that alters expression of protein kinase CK2. | 02-06-2014 |
20140161762 | DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER - The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. | 06-12-2014 |
20140193398 | POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS - Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described. | 07-10-2014 |